English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17939/22958 (78%)
Visitors : 7385880      Online Users : 180
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23863


    Title: Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts
    Authors: Lee, PJ;Ho, CC;Ho, H;Chen, WJ;Lin, CH;Lai, YH;Juan, YC;Chu, WC;Lee, JH;Su, SF;Chen, HY;Chen, JJW;Chang, GC;Li, KC;Yang, PC;Chen, HW
    Keywords: Cancer-associated fibroblasts;cancer stem cells;drug screening;tumor microenvironment;high-throughput
    Date: 2021
    Issue Date: 2022-08-05T09:44:05Z (UTC)
    Publisher: IVYSPRING INT PUBL
    ISSN: 1838-7640
    Abstract: The tumorous niche may drive the plasticity of heterogeneity and cancer stemness, leading to drug resistance and metastasis, which is the main reason of treatment failure in most cancer patients. The aim of this study was to establish a tumor microenvironment (TME)-based screening to identify drugs that can specifically target cancer stem cells (CSCs) and cancer-associated fibroblasts (CAFs) in the TME. Methods: Lung cancer patient-derived cancer cell and CAFs were utilized to mimic the TME and reproduce the stemness properties of CSCs in vitro and develop a high-throughput drug screening platform with phenotypical parameters. Limiting dilution assay, sphere-forming and ALDH activity assay were utilized to measure the cancer stemness characteristics. In vivo patient-derived xenograft (PDX) models and single-cell RNA sequencing were used to evaluate the mechanisms of the compounds in CSCs and CAFs. Results: The TME-based drug screening platform could comprehensively evaluate the response of cancer cells, CSCs and CAFs to different treatments. Among the 1,524 compounds tested, several drugs were identified to have anti-CAFs, anticancer and anti-CSCs activities. Aloe-emodin and digoxin both show anticancer and anti-CSCs activity in vitro and in vivo, which was further confirmed in the lung cancer PDX model. The combination of digoxin and chemotherapy improved therapeutic efficacy. The single-cell transcriptomics analysis revealed that digoxin could suppress the CSCs subpopulation in CAFs-cocultured cancer cells and cytokine production in CAFs. Conclusions: The TME-based drug screening platform provides a tool to identify and repurpose compounds targeting cancer cells, CSCs and CAFs, which may accelerate drug development and therapeutic application for lung cancer patients.
    URI: http://dx.doi.org/10.7150/thno.62676
    https://www.webofscience.com/wos/woscc/full-record/WOS:000704332800004
    https://ir.csmu.edu.tw:8080/handle/310902500/23863
    Relation: THERANOSTICS ,2021,v11,issue 19, P9667-9686
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML261View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback